在炎症性肠道疾病中进行微生物群移植治疗:进展和机理性见解
Daphne Moutsoglou1,2, Pavithra Ramakrishnan2, Byron P Vaughn3
1Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA.
Gut microbes
|March 10, 2025
概括
微生物种移植疗法在炎症性肠病 (IBD) 中表现有前途. 本综述探讨了影响其成功的因素,包括捐赠者/接受者特征和移植,以改善治疗结果.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 微生物种移植疗法是对炎症性肠病 (IBD) 的一种正在发展中的治疗方法.
- 了解影响其疗效和机制的因素对于临床应用至关重要.
- 目前对影响IBD治疗结果的供体,受体和移植因素的知识有限.
研究的目的:
- 审查影响微生物群移植治疗在IBD中的疗效和机制的关键因素.
- 检查与临床反应相关的供体和受体因素,对照选择和移植.
- 探索IBD中微生物群移植治疗的潜在机制和未来方向.
主要方法:
- 这项研究采用了叙事审查方法.
- 文献搜索侧重于微生物群移植治疗炎症性肠道疾病.
- 综合了影响治疗结果,机制和未来方向的关键要素.
主要成果:
- 捐赠者因素 (年龄,关系),接受者因素和对照选择显著影响微生物群移植治疗结果.
- 移植及其与临床反应的相关性是治疗成功的关键决定因素.
- 微生物群,宿主和免疫系统之间的相互作用是IBD治疗的关键机制.
结论:
- 优化供体选择,受体因素和移植策略可以提高IBD微生物群移植治疗的疗效.
- 对潜在机制的进一步研究对于完善处理方案至关重要.
- 微生物种移植疗法有可能成为IBD的未来治疗方法,目前正在进行的研究正在探索新的方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
What is Monogastric Digestion?
70.4K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
70.4K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
291
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
291
Inflammatory Bowel Disease V: Surgical Management
80
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
80
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


